Wedbush Maintains Outperform on Aclaris Therapeutics, Lowers Price Target to $8

Benzinga · 5d ago
Wedbush analyst Martin Fan maintains Aclaris Therapeutics (NASDAQ:ACRS) with a Outperform and lowers the price target from $10 to $8.